The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | IDH1/2 inhibitors for upfront AML therapy and transfusion independence
Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Amir Fathi, MD, MPH, of the Massachusetts General Hospital, Boston, MA, discusses the investigation of ivosidenib or enasidenib plus consolidation chemotherapy in newly diagnosed acute myeloid leukemia patients with IDH1 or IDH2 mutations (NCT02632708). He also covers the promise of IDH1 inhibitors for giving transfusion independence.
